SER
Serina Therapeutics Inc
2.00$
+4.1%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 9.3% | 85.0% | 82.3% | 83.3% | 72.9% | 84.4% | 85.5% | 89.4% | 92.6% | 87.5% | 97.0% | 97.0% | |
| 3.3% | 85.0% | 80.2% | 56.6% | 42.8% | 54.6% | 63.4% | 67.6% | 69.4% | 44.0% | 89.8% | 89.2% | |
| 3.3% | 85.0% | 80.2% | 56.6% | 42.8% | 54.6% | 63.4% | 67.6% | 69.4% | 68.7% | 89.8% | 89.2% | |
| 0.6% | 0.6% | 0.6% | 0.5% | 0.2% | – | – | – | – | – | – | – | |
| – | – | – | – | 15.1% | 15.6% | 14.5% | 10.6% | 7.2% | 12.1% | – | – | |
| 5.2% | 6.8% | 5.3% | 5.1% | 6.8% | – | – | – | – | – | – | – | |
| 31.9% | 54.2% | 139.7% | 253.1% | 286.0% | 92.4% | 76.8% | 81.6% | 87.2% | 100.5% | 35.4% | 27.4% | |
| 26.2% | 15.8% | 129.5% | 118.0% | 181.8% | 35.2% | 34.9% | 39.8% | 70.8% | 51.3% | 23.2% | 14.6% | |
| 12.5% | 2.8% | 94.0% | 101.5% | 140.7% | 0.0% | 0.0% | 0.0% | 24.6% | 0.0% | – | – | |
| 9.6% | 6.5% | 24.0% | 11.2% | 22.8% | 11.1% | 17.6% | 19.1% | 22.0% | 27.8% | 10.4% | 7.2% | |
| – | 7.7% | 6.4% | 6.5% | 9.3% | 0.0% | – | – | – | 42.4% | 11.0% | 12.0% | |
| 69.0% | 45.8% | -39.7% | -152.8% | -185.3% | 9.5% | 25.3% | 20.2% | 14.2% | -0.5% | 64.6% | 72.6% | |
| -1,044.7% | -369.9% | -50.1% | -216.5% | -292.9% | -659.1% | -729.9% | -621.6% | -484.7% | -913.5% | -257.9% | -297.3% | |
| 62.1% | 12.0% | 25.7% | 94.9% | 144.6% | 159.9% | 144.9% | 111.9% | 83.3% | 146.6% | 44.1% | 63.5% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.